- ￥2000 - 3400
- MultiSciences
- 3.91 pg/mL - 250 pg/mL
- 杭州
- EK102HS
- 2025年12月16日
快速发货
售后服务
技术支持
货源齐全
文献支持
企业认证
研选同类产品更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 库存：
99
- 供应商：
联科生物
- 检测范围：
3.91 pg/mL - 250 pg/mL
- 检测方法：
双抗夹心法
- 应用：
ELISA
- 适应物种：
Human
- 标记物：
HRP
- 样本：
血清，血浆，细胞培养上清及其他生物学样本
- 规格：
96T/48T
| 规格： | 96T | 产品价格： | ￥3400.0 |
|---|---|---|---|
| 规格： | 48T | 产品价格： | ￥2000.0 |
| 背景介绍 | 白细胞介素 2 (IL-2)是 15 kDa 的糖蛋白，在人类中，由位于 4 号染色体 q26 – 28 区域的单基 因编码。它是免疫系统中的一类信号分子，调控对具有免疫功能的白血球 (白细胞，通常是淋巴 细胞)的活性。IL-2 是机体对微生物感染的天然应答，区别外来和自身抗原。IL-2 通过与 IL-2 受体 来发挥功能，其受体由 3 条链组成，分别为α链 (CD25)、β链 (CD122)和γ链 (CD132)。监测血清中的 IL-2 含量为多种病理状态提供更详细的视角，包括癌症、传染病、移植排斥、 多发性硬化症、类风湿性关节炎、系统性红斑狼疮和 I 型糖尿病等。 |
| 检测原理 | 本试剂盒采用双抗体夹心酶联免疫吸附检测技术。特异性抗人IL-2抗体预包被在高亲和力的酶标板上。酶标板孔中加入标准品和待测样本，经过孵育，样本中存在的IL-2与固相抗体结合。洗涤去除未结合的物质后，加入生物素化的检测抗体孵育。洗涤去除未结合的生物素化的抗体，加入辣根过氧化物酶标记的链霉亲和素 (Streptavidin-HRP)。洗涤后，加入信号增强剂孵育，洗涤去除未结合的物质后，再次加入Streptavidin-HRP。洗涤后，加入显色底物TMB，避光显色。颜色反应的深浅与样本中IL-2的浓度成正比。加入终止液终止反应，在450 nm波长(参考波长570 - 630 nm)测定吸光度值。 |
| 组分 | 包被抗IL-2单克隆抗体的96孔聚苯乙烯酶标板 人IL-2冻干标准品 IL-2检测抗体 标准品稀释液 辣根过氧化物酶标记的链霉亲和素 信号增强剂浓缩液 信号增强剂稀释液 检测缓冲液(10×) 底物(TMB) 终止液 洗液(20×) 封板膜 |
| 分析类型 | 夹心ELISA |
| 样本类型 | 血清、血浆，细胞培养上清及其他生物学样本 |
| 板式 | 96孔板，可拆 |
| 保存 | 试剂盒未拆开，4℃保存。已拆开，标准品-20℃保存，其它4℃保存。 |
| 运输条件 | 4℃蓝冰运输 |
| 样本体积 | 20 μl |
| 灵敏度 | 0.31 pg/ml |
| 标曲图 |  |
| 标准曲线范围 | 3.91 - 250 pg/ml |
| 回收率范围 | 101 % - 129 % |
| 平均回收率 | 1.22 |
| 板间变异系数 | 6.0 % - 11.1 % |
| 板内变异系数 | 4.2 % - 4.9 % |
IL2 分子靶点信息概述
- 分子名：IL2, interleukin 2
- 基因家族：Interleukins
- 别名：IL-2; TCGF
- 全称：T cell growth factor
IL2 分子靶点综述
白细胞介素2(IL-2)是15kDa的糖蛋白，在人类中，由位于4号染色体q26–28区域的单基因编码。它是免疫系统中的一类信号分子，调控对具有免疫功能的白血球(白细胞，通常是淋巴细胞)的活性。IL-2是机体对微生物感染的天然应答，区别外来和自身抗原。IL-2通过与IL-2受体来发挥功能，其受体由3条链组成，分别为α链(CD25)、β链(CD122)和γ链(CD132)。监测血清中的IL-2含量为多种病理状态提供更详细的视角，包括癌症、传染病、移植排斥、多发性硬化症、类风湿性关节炎、系统性红斑狼疮和I型糖尿病等。
人 Human IL2 分子靶点信息
- 分子名：IL2, interleukin 2
- 别称：
- aldesleukin
- IL-2
- interleukin-2
- involved in regulation of T-cell clonal expansion
- lymphokine
- T cell growth factor
- TCGF
- 基因序列：NCBI_Gene: 3558
- 蛋白序列：UniProtKB: P60568
人 Human IL2靶点分子功能（预测）
Enables cytokine activity and interleukin-2 receptor binding activity. Involved in leukocyte activation involved in immune response; positive regulation of interleukin-17 production; and positive regulation of tyrosine phosphorylation of STAT protein. Acts upstream of or within negative regulation of B cell apoptotic process; positive regulation of B cell proliferation; and positive regulation of activated T cell proliferation. Predicted to be located in extracellular space. Implicated in several diseases, including Takayasu's arteritis; auditory system disease (multiple); autoimmune disease (multiple); carcinoma (multiple); and neurodegenerative disease (multiple). Biomarker of several diseases, including Zellweger syndrome; aggressive periodontitis; anogenital venereal wart; autoimmune disease (multiple); and uveitis (multiple).
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验该产品被引用文献或证书
- IF = 18.187 Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduction and Targeted Therapy (2022)
- IF = 14.903 Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. Acta Pharmaceutica Sinica B (2023)
- IF = 14.612 Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. Journal of the American Chemical Society (2020)
- IF = 13.751 Original research: Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. Journal for ImmunoTherapy of Cancer (2021)
- IF = 11.878 Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nature Communications (2019)
- IF = 10.618 An electrochemical biosensor for the assessment of tumor immunotherapy based on the detection of immune checkpoint protein programmed death ligand-1. BIOSENSORS & BIOELECTRONICS (2022)
- IF = 10.211 Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. JNCI-Journal of the National Cancer Institute (2019)
- IF = 9.188 Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T CellEGFR/EGFRvIII Bitargeted CAR T Cells for Cancer Treatment. Cancer Immunology Research (2018)
- IF = 8.786 A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide.. Frontiers in Immunology (2022)
- IF = 8.193 Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. CLINICAL CANCER RESEARCH (2014)
- IF = 8.11 Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy. OncoImmunology (2021)
- IF = 7.723 A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity. OncoImmunology (2022)
- IF = 7.644 Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition. OncoImmunology (2016)
- IF = 7.561 Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release. Frontiers in Immunology (2021)
- IF = 7.419 Nanobody-based CAR T cells targeting intracellular tumor antigens. BIOMEDICINE & PHARMACOTHERAPY (2022)
- IF = 7.36 A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity. CANCER LETTERS (2020)
- IF = 7.333 Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. Journal of Hematology & Oncology (2018)
- IF = 7.259 Azithromycin attenuates wheezing after pulmonary inflammation through inhibiting histone H3K27me3 hypermethylation mediated by EZH2. Clinical Epigenetics (2023)
- IF = 6.716 Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. CANCER SCIENCE (2020)
- IF = 6.688 A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells. MOLECULAR THERAPY (2017)
- IF = 6.684 Pyk2/MCU Pathway as a New Target for Reversing Atherosclerosis. Frontiers in Cell and Developmental Biology (2021)
- IF = 6.359 Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget (2015)
- IF = 6.359 Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget (2015)
- IF = 6.304 Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. Cell Death & Disease (2020)
- IF = 6.244 TGF-β1-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma.. Frontiers in Oncology (2022)
- IF = 5.328 SHTXTHHly, an extracellular secretion platform for the preparation of bioactive peptides and proteins in Escherichia coli. Microbial Cell Factories (2022)
- IF = 5.168 Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. Oncotarget (2017)
- IF = 5.108 Analysis of translation control tumor protein related to deltamethrin stress in Drosophila kc cells. CHEMOSPHERE (2019)
- IF = 4.846 Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
- IF = 4.718 Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma. JOURNAL OF IMMUNOLOGY (2019)
- IF = 4.606 Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy | Journal of Virology. JOURNAL OF VIROLOGY (2016)
- IF = 4.368 Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-κB-Signaling Axis | Journal of Virology. JOURNAL OF VIROLOGY (2018)
- IF = 4.319 Protective Effect of Hedyotis diffusa Willd. Ethanol Extract on Isoniazid-Induced Liver Injury in the Zebrafish Model. Drug Design Development and Therapy (2022)
- IF = 4.319 Study on the Mechanism of Improving HIV/AIDS Immune Function with Jian Aikang Concentrated Pill Based on Network Pharmacology Combined with Experimental Validation. Drug Design Development and Therapy (2022)
- IF = 4.225 Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein. CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
- IF = 4.219 Anemoside A3 activates TLR4-dependent M1-phenotype macrophage polarization to represses breast tumor growth and angiogenesis. TOXICOLOGY AND APPLIED PHARMACOLOGY (2021)
- IF = 4.218 Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy. CYTOTHERAPY (2020)
- IF = 4.183 Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
- IF = 4.157 Inflammatory Cytokines Changed in Patients With Depression Before and After Repetitive Transcranial Magnetic Stimulation Treatment. Frontiers in Psychiatry (2022)
- IF = 4.124 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. Journal of Translational Medicine (2020)
- IF = 4.06 Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy. American Journal of Translational Research (2021)
- IF = 3.831 Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Frontiers in Pharmacology (2018)
- IF = 3.659 Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. CANCER BIOLOGY & THERAPY (2020)
- IF = 3.633 Vitamin D deficiency is associated with thyroid autoimmunity: results from an epidemiological survey in Tianjin, China. ENDOCRINE (2021)
- IF = 3.591 Discovery of modulators for the PD-1/PD-L1 interaction by molecular simulation and bioassay. NEW JOURNAL OF CHEMISTRY (2021)
- IF = 3.452 Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine. Human Vaccines & Immunotherapeutics (2022)
- IF = 3.357 The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome. Cancer Medicine (2019)
- IF = 3.357 Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Cancer Medicine (2019)
- IF = 3.297 An intronic polymorphism of NFATC1 gene shows a risk association with biopsy-proven acute rejection in renal transplant recipients. Annals of Translational Medicine (2020)
- IF = 3.249 Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells. Journal of Cancer (2018)
- IF = 3.152 Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors. IMMUNOBIOLOGY (2022)
- IF = 3.138 Different effects of lipoteichoic acid from C. butyricum and S. aureus on inflammatory responses of HT-29 cells. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2016)
- IF = 3.046 IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell. OncoTargets and Therapy (2019)
- IF = 2.886 EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer. Cancer Management and Research (2020)
- IF = 2.886 JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination. Cancer Management and Research (2020)
- IF = 2.884 Hyperbaric Oxygen Alleviates the Inflammatory Response Induced by LPS Through Inhibition of NF-κB/MAPKs-CCL2/CXCL1 Signaling Pathway in Cultured Astrocytes. INFLAMMATION (2018)
- IF = 2.65 Ultrasound-Guided Percutaneous Transhepatic Gallbladder Drainage Improves the Prognosis of Patients with Severe Acute Cholecystitis. Evidence-based Complementary and Alternative Medicine (2022)
- IF = 2.348 Regulation of CBL and ESR1 expression by microRNA-22‑3p, 513a-5p and 625-5p may impact the pathogenesis of dust mite-induced pediatric asthma. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
- IF = 2.327 Changes in peripheral blood cytokines in patients with severe fever with thrombocytopenia syndrome. JOURNAL OF MEDICAL VIROLOGY (2021)
- IF = 2.284 Effect of laser therapy on expression of angio- and fibrogenic factors, and cytokine concentrations during the healing process of human pressure ulcers. International Journal of Medical Sciences (2018)
- IF = 2.276 Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer. Biomed Research International (2020)
- IF = 1.813 Treatment Efficacy of Chuang Ling Ye, a Traditional Chinese Herbal Medicine Compound, on Idiopathic Granulomatous Mastitis: A Randomized Controlled Trial. Evidence-based Complementary and Alternative Medicine (2020)
- IF = 1.497 Expression of coinhibitory PD-L1 on CD4+CD25+FOXP3+ regulatory T cells is elevated in patients with acute coronary syndrome. CORONARY ARTERY DISEASE (2015)
技术资料需要更多技术资料 索取更多技术资料
研选
Human IL-2 High Sensitivity ELISA Kit（人白介素2 高敏ELISA试剂盒）
￥2000 - 3400
